GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of ...